sj-doc-1-taj-10.1177_20406223231206225 – Supplemental material for Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials

Supplemental material, sj-doc-1-taj-10.1177_20406223231206225 for Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials by Hsien-Yi Chiu, Yi-Teng Hung and Yu-Huei Huang in Therapeutic Advances in Chronic Disease</p

sj-docx-1-taj-10.1177_20406223231168488 – Supplemental material for Lifetime risk, life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for psoriasis in Taiwan: a nationwide cohort followed from 2000 to 2017

Supplemental material, sj-docx-1-taj-10.1177_20406223231168488 for Lifetime risk, life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for psoriasis in Taiwan: a nationwide cohort followed from 2000 to 2017 by Hsien-Yi Chiu, Joung-Liang Lan and Ying-Ming Chiu in Therapeutic Advances in Chronic Disease</p

Demographic features and final outcomes.

Demographic features and final outcomes.</p

Description of the patient with seroconversion outcome.

Description of the patient with seroconversion outcome.</p

Final outcomes corresponding to the cumulative exposure time.

Final outcomes corresponding to the cumulative exposure time.</p

Comparison between persistently seronegative group and seroconversion group.

Comparison between persistently seronegative group and seroconversion group.</p

Results of QuantiFERON-TB Gold In-Tube test.

Results of QuantiFERON-TB Gold In-Tube test.</p

sj-doc-1-taj-10.1177_20406223211046685 – Supplemental material for Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice

Supplemental material, sj-doc-1-taj-10.1177_20406223211046685 for Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice by Yi-Teng Hung, Yu-Jr Lin, Hsien-Yi Chiu and Yu-Huei Huang in Therapeutic Advances in Chronic Disease</p

Mass Specthoscope: A Hand-held Extendable Probe for Localized Noninvasive Sampling of Skin Volatome for Online Analysis

Human skin emits a unique set of volatile organic compounds (VOCs). These VOCs can be probed in order to obtain physiological information about the individuals. However, extracting the VOCs that emanate from human skin for analysis is troublesome and time-consuming. Therefore, we have developed “Mass Specthoscope”a convenient tool for rapid sampling and detecting VOCs emitted by human skin. The hand-held probe with a pressurized tip and wireless button enables sampling VOCs from surfaces and their transfer to the atmospheric pressure chemical ionization source of quadrupole time-of-flight mass spectrometer. The system was characterized using chemical standards (acetone, benzaldehyde, sulcatone, α-pinene, and decanal). The limits of detection are in the range from 2.25 × 10–5 to 3.79 × 10–5 mol m–2. The system was initially tested by detecting VOCs emanating from porcine skin spiked with VOCs as well as unspiked fresh and spoiled ham. In the main test, the skin of nine healthy participants was probed with the Mass Specthoscope. The sampling regions included the armpit, forearm, and forehead. Numerous skin-related VOC signals were detected. In the final test, one participant ingested a fenugreek drink, and the participant’s skin surface was probed using the Mass Specthoscope hourly during the 8 h period. The result revealed a gradual release of fenugreek-related VOCs from the skin. We believe that this analytical approach has the potential to be used in metabolomic studies and following further identification of disease biomarkersalso in noninvasive diagnostics

sj-doc-1-taj-10.1177_20406223221091188 – Supplemental material for Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis

Supplemental material, sj-doc-1-taj-10.1177_20406223221091188 for Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis by Hsien-Yi Chiu, Yi-Teng Hung, Shi-Wei Huang and Yu-Huei Huang in Therapeutic Advances in Chronic Disease</p